Related Experiment Video
Updated: Jun 17, 2025
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
The Cytokine Storm of Multicentric Castleman Disease
1Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, PA, USA. davidfa@pennmedicine.upenn.edu.
Insights
Cytokine storm disorders, like multicentric Castleman disease (MCD), share symptoms and can have various triggers. Targeting interleukin-6 (IL-6) with tocilizumab effectively treats idiopathic MCD (iMCD).
Area of Science:
- Immunology
- Pathology
- Pharmacology
Background:
- Cytokine storm disorders present with overlapping clinical features and can be triggered by diverse factors.
- Multicentric Castleman disease (MCD) exemplifies this, with causes including viral infections, neoplastic cells, or idiopathic origins.
- Idiopathic MCD (iMCD) is a key example of a cytokine storm disorder responsive to targeted therapy.
Purpose of the Study:
- To highlight the diverse triggers and shared features of cytokine storm disorders.
- To present iMCD as a model for targeted cytokine inhibition therapy.
- To discuss the historical and ongoing use of tocilizumab in cytokine storm management.
Main Methods:
- Review of clinical features and triggers of cytokine storm disorders.
- Case study analysis of idiopathic MCD (iMCD) treatment.
- Pharmacological review of anti-interleukin-6 (IL-6) receptor monoclonal antibody therapy.
Main Results:
- Multiple triggers can induce similar cytokine storm syndromes, including MCD.
- Targeted neutralization of interleukin-6 (IL-6) with tocilizumab demonstrated efficacy in treating iMCD.
- Tocilizumab has been utilized in various cytokine storm settings for over three decades.
Conclusions:
- Cytokine storm disorders are complex, often sharing clinical presentations despite varied etiologies.
- Targeted cytokine inhibition, exemplified by anti-IL-6 therapy for iMCD, represents a significant advancement in managing these conditions.
- The long-term application of tocilizumab underscores its role in addressing cytokine-mediated inflammatory diseases.
Abstract:
As described throughout this book, different triggers can elicit a variety of different cytokine storm disorders that share overlapping clinical features (Fig. 31.1). Even within a particular cytokine storm disorder, multiple different triggers can elicit the syndrome. Like HLH, multicentric Castleman disease (MCD) serves as a great example of this as it can be caused by a viral infection, neoplastic cell population, or an unknown cause. Furthermore, the idiopathic subtype of MCD (iMCD) provides one of the first examples of a cytokine storm disorder that could be abrogated with targeted neutralization of a single cytokine when inhibition with the anti-interleukin-6 (IL-6) receptor monoclonal antibody tocilizumab was shown to effectively treat iMCD in the 1990s. Of course, this "iMCD treatment," tocilizumab, has been used in a variety of cytokine storm settings over the last 30+ years.
More Related Videos
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
01:15Differentiation of Common Myeloid Progenitor Cells
01:20The JAK-STAT Signaling Pathway